Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vancomycin

R Fekety

    The Medical Clinics of North America
    |January 1, 1982
    PubMed
    Summary
    This summary is machine-generated.

    Vancomycin is safe and effective for most patients, but should be avoided with other kidney-damaging drugs. Proper use ensures efficacy and safety across all age groups.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2000
    Same author

    The hunt for Clostridium difficile: 21-year follow-up of a stool specimen sent for culture.

    Lancet (London, England)·1999
    Same author

    Recurrent Clostridium difficile disease: epidemiology and clinical characteristics.

    Infection control and hospital epidemiology·1999
    Same author

    Treatment with ganciclovir of adenovirus pneumonia in a cardiac transplant patient.

    The American journal of medicine·1997
    Same author

    Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee.

    The American journal of gastroenterology·1997
    Same author

    Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·1997
    Same journal

    Care Transitions Continue to Evolve.

    The Medical clinics of North America·2026
    Same journal

    Navigating the Gaps: A Comprehensive Overview of Care Transitions Across the Continuum.

    The Medical clinics of North America·2026
    Same journal

    Care Transitions and Value-Based Payment Models in the United States.

    The Medical clinics of North America·2026
    Same journal

    Technology and Innovation in Care Transitions: Imagining the Future of Postdischarge Care.

    The Medical clinics of North America·2026
    Same journal

    Primary Care, Specialists, and Hospitals: Bridging the Gaps in Communication and Coordination.

    The Medical clinics of North America·2026
    Same journal

    Social Determinants of Health: Unique Considerations in Transitions of Care.

    The Medical clinics of North America·2026
    See all related articles

    Area of Science:

    • Pharmacology
    • Nephrology
    • Infectious Diseases

    Background:

    • Vancomycin is a critical antibiotic for treating serious bacterial infections.
    • Concerns regarding vancomycin's nephrotoxicity have historically limited its use.
    • Understanding vancomycin's safety profile is essential for optimal patient care.

    Purpose of the Study:

    • To evaluate the nephrotoxic potential of vancomycin.
    • To assess the efficacy and safety of vancomycin in diverse patient populations.
    • To identify drug incompatibilities with vancomycin in intravenous solutions.

    Main Methods:

    • Review of existing clinical data and pharmacological studies on vancomycin.
    • Analysis of adverse event reports related to vancomycin use.

    Related Experiment Videos

  • Assessment of drug interaction studies concerning vancomycin.

    • Main Results:

    • Vancomycin exhibits less nephrotoxicity than previously assumed.
    • Parenteral vancomycin use should be minimized when co-administered with other nephrotoxic agents.
    • Vancomycin demonstrates efficacy and safety in infants, children, and adults when used appropriately.
    • Significant incompatibilities exist between vancomycin and drugs like chloramphenicol, adrenocorticosteroids, and methicillin in IV solutions.

    Conclusions:

    • Vancomycin can be used safely and effectively across pediatric and adult populations.
    • Careful consideration of concurrent nephrotoxic medications is crucial during vancomycin therapy.
    • Awareness of vancomycin's intravenous incompatibilities is vital for safe drug administration.